top of page

ChapterDX MLSTnext™ Cyclospora Target Enrichment

Reliable identification in just 14 hours 

Contact us to learn more

<14 Hours 

The total workflow is designed for efficiency, requiring less than 14 hours to complete. This timeline includes 6 hours of benchwork and incubation time, approximately 7 hours of sequencing, and less than 30 minutes for automated data analysis.

Image by Nigel Hoare

Low amount of cDNA 

This assay requires low amounts of input DNA and is suitable for small, medium and high-throughput sample scales. 

Technology

The Chapter Diagnostics MLSTnext™ Cyclospora target enrichment NGS kit offers a high-resolution, multiplexed solution for identifying Cyclospora variants. By targeting specific informative loci across the genome, this kit replaces traditional, labor-intensive subtyping with a streamlined Next-Generation Sequencing (NGS) approach optimized for Illumina platforms.

Optimized Workflow

The assay is designed for maximum efficiency, following a logical seven-step progression:

  1. DNA extraction (not provided)

  2. First PCR

  3. Pooling and purification

  4. Target enrichment

  5. Second PCR

  6. Pooling and purification

  7. Next-generation sequencing​

 

With a total turnaround time of less than 14 hours—comprising 6 hours of laboratory procedures, 7 hours of sequencing, and 30 minutes of data analysis—this assay is designed for high sensitivity with low DNA input. Its flexible architecture is equally suited for small, medium, and high-throughput sample scales, offering a rapid and scalable solution for modern molecular diagnostics.

ChapterDx MLSTnext™ Cyclospora Target Enrichment NGS Assay Workflow

Gemini_Generated_Image_4n0wu64n0wu64n0w.png

Cat No./ Size     C7821A /96 rxns
                          (includes12 indexing per sequencing run*)                                               
                           *More indexing options are available
   

For Research Use Only (RUO)

Patent Pending

1455 Adams Dr #2162

Menlo Park, CA 94025

© 2022 Chapter Diagnostics Inc.  All rights reserved.

bottom of page